Abstract Non-small cell lung cancer is the most common form of lung cancer, accounting for about 85% of all cases and is further subdivided into adenocarcinoma, squamous cell, and large cell carcinoma. Necitumumab (Portrazza TM , Eli Lilly and Company) is an anti-epidermal growth factor receptor monoclonal antibody approved for the first-line treatment of squamous cell non-small cell lung cancer in combination with cisplatin and gemcitabine. The safety and efficacy of necitumumab has been evaluated in two-phase III clinical trials, one demonstrating a lack of efficacy in non-squamous non-small cell lung cancer and another demonstrating improvement in overall survival and progression-free survival in squamous cell non-small cell lung cancer. Necitumumab is associated with adverse events such as infusion reactions, hypomagnesemia, diarrhea, and dermatological toxicities. Although considered a safe and effective treatment option for squamous cell non-small cell lung cancer, the clinical utility of necitumumab may be limited due to the high cost of the drug as well as added toxicity when combined with cisplatin and gemcitabine. Several clinical trials are ongoing in order to further investigate the utilization of necitumumab.
Introduction
Lung cancer continues to be one of the most common malignancies and the leading cause of cancer-related deaths in men and women in the USA. 1 It is estimated that there will be over 224,000 new cases of lung cancer and about 158,000 deaths secondary to lung cancer in 2016.
Lung cancer is comprised of three distinct types: small cell lung cancer, non-small cell lung cancer, and lung carcinoid tumors. Non-small cell lung cancer (NSCLC) represents a group of heterogeneous lung malignancies, accounting for about 85% of all lung cancers. 1 NSCLC is comprised of three distinct histologies: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Oncogenic mutations have been identified as key factors for the growth and proliferation of malignant cells in some cases of NSCLC, specifically epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) fusion protein rearrangements. The management of NSCLC is dependent on the stage of disease, histology, mutational status, and Eastern Cooperative Oncology Group (ECOG) performance status of individual patients.
Squamous cell NSCLC comprises about 25% of all lung cancer diagnoses. 1 Initial treatment of metastatic squamous cell NSCLC generally consists of platinumbased combination chemotherapy, such as carboplatin and paclitaxel, carboplatin and protein-bound paclitaxel, and cisplatin and gemcitabine, if a patient's performance status permits. 2 While the treatment of non-squamous NSCLC incorporates targeted therapies for oncogenic mutations such as monoclonal antibodies or tyrosine kinase inhibitors into front-line treatment in addition to chemotherapy, historically, squamous NSCLC has been without these specialized treatment modalities. Addition of the monoclonal antibody bevacizumab to chemotherapy in squamous cell NSCLC has been limited due to an increased risk of serious or fatal pulmonary hemorrhage reported in this patient population. 3 Patients with squamous NSCLC rarely harbor genetic mutations such as EGFR and ALK mutations, precluding the use of agents that specifically target these oncogenic pathways. Therefore, the mainstay of therapy for squamous NSCLC has been cytotoxic chemotherapy.
In November 2015, the U.S. Food and Drug Administration (FDA) approved necitumumab (Portrazza TM , Eli Lilly and Company), the first monoclonal antibody indicated for the first-line treatment of metastatic squamous cell NSCLC, in combination with cisplatin and gemcitabine. 4 This paper will review the role of this recently approved therapeutic agent, necitumumab, for the treatment of metastatic squamous cell NSCLC.
Data selection
Literature searches were performed in PubMed MEDLINE (July 2006 to July 2016) and ClinicalTrials.gov using the search terms necitumumab, LY3012211 or IMC-11F8 to identify published clinical trials as well as ongoing studies. Limits applied to the PubMed MEDLINE search result included human and full-text availability. Abstracts presented at meetings of the American Society of Clinical Oncology (2011-2016) were also included. One phase I and two phase III trials were identified evaluating the safety and efficacy of necitumumab in patients with NSCLC. The manufacturer's prescribing information was also included in order to supplement previously published data.
Pharmacology
Necitumumab is a fully human IgG1 monoclonal antibody that targets and binds to the EGFR, preventing the interactions between the receptor and its ligands. The expression of EGFR and activation via binding with ligands such as epidermal growth factor, transforming growth factor-alpha, and amphiregulin may promote cellular proliferation, angiogenesis, prevent apoptosis, and alter cellular differentiation. 6 Inactivation of EGFR by necitumumab can lead to degradation of the receptor as well as antibody-dependent cellular cytotoxicity in cells that express EGFR.
Pharmacokinetics
Necitumumab demonstrates dose-dependent pharmacokinetics according to population pharmacokinetic analysis. 5 After the administration of necitumumab on days 1 and 8 of a 21-day cycle, the predicted mean total system clearance at steady state is 14.1 mL/h, and steady state is predicted to be reached in about 100 days. The steady-state volume of distribution and elimination half-life is 7.0 L and 14 days, respectively.
The safety and efficacy of necitumumab have not been formally evaluated in patients with hepatic or renal impairment. 5 However, based on population pharmacokinetic analysis, there is no apparent influence of renal or hepatic impairment on the extent of exposure to necitumumab in this patient population. Therefore, no dose adjustments are necessary in patients with hepatic or renal impairment.
Clinical efficacy
Kuenen et al. conducted a phase I trial in 60 patients with advanced solid tumors in order to investigate the maximum tolerated dose (MTD) and recommended dose of necitumumab. 7 Patients were first randomized to one of two arms, Arm A and Arm B, and then assigned to a specific dosing cohort consisting of 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, and 1000 mg. All subjects received one initial dose of necitumumab at their assigned dose level followed by a two-week treatment-free period in order to obtain pharmacokinetic sampling. Following the two-week treatment-free period, Arm A and Arm B received necitumumab weekly and every other week, respectively.
Two patients receiving 1000 mg every two weeks experienced dose-limiting toxicity of a grade 3 headache, establishing 800 mg as the MTD. Otherwise, necitumumab was found to be relatively well tolerated in both treatment arms. The most common adverse drug reaction was skin toxicity, such as dry skin, pruritis, skin fissures, and acneiform rash, which occurred in about 80% of subjects in each arm. Stable disease was observed in 16 subjects, 8 in each treatment arm, and 17 patients and 4 patients demonstrated progression-free survival at 3 months and 9 months, respectively. From these results, the authors concluded that necitumumab was considered to be relatively safe and warranted further investigation in larger clinical trials.
INSPIRE was a multicenter, open-label, randomized, controlled phase III trial evaluating patients with previously untreated, stage IV, non-squamous NSCLC. 8 A total of 633 patients were randomized to receive cisplatin, pemetrexed, and necitumumab (n ¼ 315), or cisplatin and pemetrexed (n ¼ 318). The study was open-label because necitumumab can cause an acneiform rash which would unmask most patients and investigators to the treatment assignments. All patients received cisplatin 75 mg/m 2 and pemetrexed 500 mg/m 2 intravenously on day 1 of a three-week cycle for a maximum of six cycles. Patients in the experimental group received necitumumab 800 mg intravenously on days 1 and 8 of the three-week cycle. Patients on necitumumab who completed six cycles of chemotherapy and lacked evidence of disease progression continued necitumumab until documentation of progressive disease or intolerable side effects. Patients who received chemotherapy alone were only monitored until evidence of disease progression. The primary endpoint was overall survival (OS); secondary outcomes included progression-free survival (PFS), safety, time to treatment failure, and objective response.
The study was stopped early by an independent data monitoring committee because patients receiving necitumumab had an increase in non-fatal and fatal thromboembolic events and an increased overall number of deaths from any cause. Additionally, fatal thromboembolic events were more likely to occur during the first two cycles. The OS in the necitumumab plus chemotherapy group was 11.3 months versus 11.5 months in the chemotherapy alone group (HR 1.01 [95% CI 0.84-1.21]; p ¼ 0.96). Grade 3 or higher adverse events occurred in 72% of the necitumumab treatment group and in 59% of the chemotherapy alone group. The authors concluded that the addition of necitumumab to cisplatin and pemetrexed as firstline therapy does not improve overall survival in patients with previously untreated, stage IV, nonsquamous NSCLC.
SQUIRE was a multicenter, open-label, randomized phase III trial evaluating patients with previously untreated stage IV squamous cell NSCLC. 9 A total of 1093 patients were randomized into two groups. Both groups received cisplatin 75 mg/m 2 intravenously over 120 min on day 1 and gemcitabine 1250 mg/m 2 intravenously over 30 min on days 1 and 8 of a three-week cycle for a maximum of six cycles. The experimental group received necitumumab 800 mg intravenously on days 1 and 8 of the three-week cycle. Necitumumab could be continued after six cycles if there was no evidence of disease progression or intolerable side effects. The primary outcome was OS; secondary outcomes included progression-free survival (PFS), objective response, time to treatment failure, and safety of necitumumab.
The OS in months for the experimental group was 11.5 and 9. 
Safety
The most common adverse events associated with necitumumab include hypomagnesemia, infusion-related reactions, diarrhea, and dermatological reactions such as dermatitis and acneiform rash.
5 Venous and arterial thromboembolic events, although rare, have been reported. Necitumumab currently harbors block box warnings for the risk of cardiopulmonary arrest or sudden death and hypomagnesemia. It is recommended to closely monitor serum electrolytes such as potassium, magnesium, and calcium and to give electrolyte repletion as needed.
Dermatologic toxicity may occur during therapy with necitumumab. 5 This may include dermatitis, acneiform rash, dry skin, pruritus, erythema, and maculopapular rash. Onset of necitumumab-induced dermatological toxicity is usually within the first two weeks of therapy. Patients should avoid or minimize sunlight exposure in order to prevent dermatological reactions; this can be accomplished with the use of protective clothing and sunscreen. In the event of a grade 3 dermatological reaction, the dose of necitumumab should be reduced to 400 mg for at least one treatment cycle and may be increased to 600 mg and then 800 mg in subsequent cycles if symptoms do not continue to worsen. Necitumumab should be permanently discontinued if a life-threatening, grade 4 dermatological reaction occurs.
Hypomagnesemia can be one of the most clinically significant and common electrolyte abnormalities that may occur with necitumumab therapy, with severe grade 3 or 4 hypomagnesemia occurring in about 20% of patients receiving necitumumab-based therapy. Serum magnesium, calcium, and potassium should be monitored prior to each infusion of necitumumab and for at least eight weeks after discontinuation of therapy. Electrolyte abnormalities have a median time of development of six weeks following the initiation of necitumumab. Electrolytes should be repleted as needed and therapy should be held for severe grade 3 or 4 abnormalities, with future cycles administered once electrolytes have improved to at least a grade 2 or less.
Infusion reactions may occur with the administration of necitumumab, typically with the first or second dose.
5 Despite the risk for these reactions, premedication prior to necitumumab administration was not routinely given in the SQUIRE trial. 9 In the event of a patient developing a grade 1 or 2 infusion reaction, diphenhydramine or an equivalent antihistamine should be given prior to all subsequent necitumumab doses.
5 If a grade 1 or 2 infusion reaction continues to recur following the use of diphenhydramine, premedication should be further altered to also include acetaminophen and dexamethasone or an equivalent corticosteroid. The infusion rate should be reduced by 50% for a grade 1 reaction; the infusion should be temporarily interrupted to allow symptoms to resolve in the event of a grade 2 infusion reaction. Necitumumab should be discontinued if a serious or life-threatening infusion reaction occurs.
Dosing and administration
The recommended dosing of necitumumab is a fixed dose of 800 mg administered via intravenous infusion over 60 min on days 1 and 8 of a 21-day cycle in combination with cisplatin on day 1 and gemcitabine on days 1 and 8 of each cycle.
5 Following six cycles of treatment without disease progression or intolerable toxicity, necitumumab can be continued as maintenance monotherapy given on the same administration cycle until disease progression or intolerable toxicity.
Place in therapy and future directions
Necitumumab currently has a category 3 recommendation for the first-line treatment of squamous cell NSCLC in combination with cisplatin and gemcitabine according to the National Comprehensive Cancer Network (NCCN) guidelines. 2 It has received this recommendation in patients with both an ECOG performance status of 0-1 and 2. Category 3 denotes that there is a disagreement from NCCN that the utilization of an intervention is appropriate. Given the modest improvement in overall survival, added toxicity, and significant cost associated with therapy, the addition of necitumumab to front-line therapy with cisplatin and gemcitabine is not preferred by the NCCN guidelines. Platinum-based chemotherapy doublets such as carboplatin/nab-paclitaxel, cisplatin/gemcitabine, and carboplatin/paclitaxel continue to be preferred agents by the NCCN guidelines for the front-line treatment of squamous cell NSCLC.
A recent cost-analysis study was conducted to evaluate if there is any cost-effectiveness associated with the addition of necitumumab to standard cisplatin and gemcitabine chemotherapy in metastatic squamous cell NSCLC. 10 The investigators developed a Markov model to evaluate the potential cost and effectiveness of treating metastatic squamous cell NSCLC with either gemcitabine and cisplatin for six cycles or gemcitabine, cisplatin, and necitumumab for six cycles followed by maintenance necitumumab monotherapy. The model then incorporated potential second-line options such as docetaxel, vinorelbine, and erlotinib. The authors found that the addition of necitumumab to front-line cisplatin and gemcitabine in this patient population produced a survival benefit of 0.15 life years and 0.11 quality-adjusted life-years. The authors concluded that their study helped to provide a value-based cost of necitumumab. Despite these findings, the NCCN guidelines still do not prefer the addition of necitumumab to cisplatin and gemcitabine for the front-line treatment of squamous cell NSCLC. 2 Currently, there are several ongoing clinical trials investigating necitumumab in the treatment of NSCLC in several different settings (Table 1) . It is currently being studied in combination with pre-existing agents, such as osimertinib, pembrolizumab, nabpaclitaxel, and carboplatin, as well as with new agents under investigation, abemaciclib and AZD9291. Necitumumab is currently being evaluated in the second-line setting following treatment failure or progression with front-line EGFR tyrosine kinase inhibitors and platinum-based chemotherapy. The role of necitumumab in the first-line setting for the treatment of squamous cell NSCLC also continues to be evaluated in an ongoing trial of necitumumab in combination with nab-paclitaxel and carboplatin. With time, these ongoing clinical trials may shed further light on the potential therapeutic benefit and optimal place in therapy for this new agent.
Conclusion
With evidence of increased overall survival and progression-free survival, necitumumab in combination with cisplatin and gemcitabine is an option for the treatment of advanced and metastatic squamous cell NSCLC. Its role may be limited due to high cost and increased incidence of adverse events in addition to standard first-line platinum-based chemotherapy in the treatment of NSCLC. Several ongoing clinical trials are underway to further evaluate the therapeutic benefit of necitumumab in patients with squamous cell NSCLC.
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